1
Clinical Trials associated with Autologous cultured urological tissue cells (inRegen)A Phase 1, Open-Label Safety and Delivery Optimization Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Chronic Kidney Disease (CKD)
The primary purpose of this study is to assess the safety and optimal delivery of the Neo-Kidney Augment (NKA) when implanted at one site in a recipient kidney. NKA is made from expanded autologous, homologous, selected renal cells (SRC) obtained from the patient's kidney biopsy.
100 Clinical Results associated with Autologous cultured urological tissue cells (inRegen)
100 Translational Medicine associated with Autologous cultured urological tissue cells (inRegen)
100 Patents (Medical) associated with Autologous cultured urological tissue cells (inRegen)
100 Deals associated with Autologous cultured urological tissue cells (inRegen)